FDA panel to wrangle with Spiriva Respimat's 'complex' history
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's Spiriva Respimat (tiotropium bromide) has had a complicated history, which includes an initial rejection by the FDA as a treatment for chronic obstructive pulmonary disease (COPD).